{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"70.94","value":"288.06"},{"groupId":"OG001","spread":"27.76","value":"1426.00"},{"groupId":"OG002","spread":"40.77","value":"2237.46"},{"groupId":"OG003","spread":"28.31","value":"6525.37"},{"groupId":"OG004","spread":"30.47","value":"12886.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"title":"Cycle 1 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"75.32","value":"240.31"},{"groupId":"OG001","spread":"16.14","value":"1207.68"},{"groupId":"OG002","spread":"36.97","value":"1869.52"},{"groupId":"OG003","spread":"36.04","value":"5149.74"},{"groupId":"OG004","spread":"43.57","value":"8303.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"title":"Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.43","value":"252.20"},{"groupId":"OG001","spread":"18.63","value":"957.58"},{"groupId":"OG002","spread":"44.40","value":"1323.91"},{"groupId":"OG003","spread":"57.06","value":"3467.58"},{"groupId":"OG004","spread":"38.27","value":"5329.63"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"35"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"35"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"description":"Maximum observed serum concentration, obtained directly from the observed concentration versus time data.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Sotatercept 0.1 mg/kg administered via subcutaneous injection every third week (Q3W). Participants were randomized to either the 0.1 mg/kg arm or the 0.3 mg/kg arm. Efficacy and safety data were assessed by a Steering Committee. Based upon the occurrence of dose-limiting toxicity (DLT) in ≤ 1/5 subjects in Cycle 1 in the 0.1 mg/kg and 0.3 mg/kg treatment groups, the 0.5 mg/kg treatment group began inclusion in the randomization scheme.","id":"OG000","title":"Sotatercept 0.1 mg/kg"},{"description":"Sotatercept 0.3 mg/kg administered via subcutaneous injection every third week (Q3W). Participants were randomized to either the 0.1 mg/kg arm or the 0.3 mg/kg arm. Efficacy and safety data were assessed by a Steering Committee. Based upon the occurrence of dose-limiting toxicity (DLT) in ≤ 1/5 subjects in Cycle 1 in the 0.1 mg/kg and 0.3 mg/kg treatment groups, the 0.5 mg/kg treatment group began inclusion in the randomization scheme.","id":"OG001","title":"Sotatercept 0.3 mg/kg"},{"description":"Sotatercept 0.5 mg/kg administered via subcutaneous injection every third week (Q3W). Participants were randomized to one of the active treatment arms. Efficacy and safety data were assessed by a Steering Committee. Based upon the occurrence of dose-limiting toxicity (DLT) in ≤ 1/6 subjects in Cycle 1 in the 0.5 mg/ kg treatment group, the 1.0 mg/kg treatment group began inclusion in the randomization scheme.","id":"OG002","title":"Sotatercept 0.5 mg/kg"},{"description":"Sotatercept 1.0 mg/kg administered via subcutaneous injection every third week (Q3W). Participants were randomized to one of the active treatment arms. Efficacy and safety data were assessed by a Steering Committee. Based upon the occurrence of dose-limiting toxicity (DLT) in ≤ 1/6 subjects in Cycle 1 in the 1.0 mg/ kg treatment group, the 2.0 mg/kg treatment group began inclusion in the randomization scheme. Following evaluation of all treatment group data by the Steering Committee, enrollment continued only in the 1.0 mg/kg arm because the arm had the greatest frequency of erythroid hematological improvement (HI-E).","id":"OG003","title":"Sotatercept 1.0 mg/kg"},{"description":"Sotatercept 2.0 mg/kg administered via subcutaneous injection every third week (Q3W). Participants were randomized to one of the active treatment arms. Efficacy and safety data were assessed by a Steering Committee. The 2.0 mg/kg sotatercept dose was reduced to 1.5 mg/kg for ongoing and newly enrolled participants by protocol amendment.","id":"OG004","title":"Sotatercept 2.0 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) population includes participants with a sufficient amount of post-dose quantifiable PK sotatercept profile.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 8 and !5 up to Cycle 2 Day 1","title":"Pharmacokinetic Parameters of Sotatercept: Serum Concentration at Various Study Timepoints","type":"SECONDARY","unitOfMeasure":"ng/mL"}